Spruce Biosciences, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | $3.2M | $-30.6M | $3.9M |
| FY2020 | $1.9M | $149.4M | $157.2M |
| FY2021 | $4.9M | $111.4M | $42.7M |
| FY2022 | $3.3M | $68.5M | $24.5M |
| FY2023 | $1.7M | $76.5M | $96.3M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | $3.2M | $-30.6M | $3.9M |
| FY2020 | $1.9M | $149.4M | $157.2M |
| FY2021 | $4.9M | $111.4M | $42.7M |
| FY2022 | $3.3M | $68.5M | $24.5M |
| FY2023 | $1.7M | $76.5M | $96.3M |